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584 The Journal of Thoracic and CardioObjective: The bioactive peptide endothelin modulates left ventricular function by
changing afterload, coronary vascular tone, and myocardial contractility. However,
whether increased plasma endothelin levels observed in patients during and after
coronary revascularization and cardiopulmonary bypass reflect actual myocardial
interstitial levels are unknown.
Methods: A microdialysis probe (outer diameter: 0.77 mm; length: 4 mm) was
placed in the left ventricular apical midmyocardium in 20 patients and myocardial
interstitial fluid was collected (2.5 L/min) at baseline and up to 30 minutes after
cardiopulmonary bypass. Myocardial interstitial and systemic arterial endothelin
were measured by radioimmunoassay.
Results: Baseline myocardial interstitial endothelin was over 6-fold higher than
plasma (20.11  2.07 vs 3.19  0.25 fmol/mL, P  .05). Plasma endothelin
increased by 23%  12% at 60 minutes of cardiopulmonary bypass whereas
myocardial interstitial endothelin increased by 105%  24%, P  .05), and this
change was higher than in the plasma (P  .05). Although no further change in
plasma endothelin occurred during cardiopulmonary bypass, myocardial interstitial
levels increased further after crossclamp removal (400%  75%) and remained
significantly higher than plasma at separation from cardiopulmonary bypass.
Conclusion: The unique findings of this study were 2-fold: First, significant com-
partmentalization of endothelin exists within the human myocardium. Second, a
significantly higher and temporally disparate change in myocardial interstitial en-
dothelin occurs during and after cardiopulmonary bypass when compared with
systemic levels. These dynamic changes in myocardial endothelin likely influence
coronary vascular tone and contractility.
The bioactive peptide endothelin-1 (ET) modulates left ventricular(LV) function by changing afterload and coronary vascular tone andthrough direct effects on myocardial contractility.1-3 Increased ETproduction has been demonstrated in a number of cardiovasculardisease states including pulmonary hypertension, myocardial infarc-tion, and congestive heart failure.1-5 Increased plasma ET has also
been documented in patients undergoing cardiac surgery.6-10 Moreover, past studies
have demonstrated that in patients undergoing coronary revascularization and car-
vascular Surgery ● March 2005
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Pdiopulmonary bypass (CPB), systemic ET levels increase
during the operative procedure and can remain elevated
postoperatively.6-9
ET is produced by a number of cell types including
endothelial cells, smooth muscle cells, and cardiac myo-
cytes.1-4 A past study demonstrated that in patients under-
going cardiac surgery, myocardial production of ET in-
creased after CPB.7 These findings suggest that ET may be
produced and released into the myocardial interstitium.
However, local myocardial interstitial ET levels have never
Figure 1. A linear regression analysis was used for bo
fmol/mL) ET measurements. The x-axis denotes the qu
denotes the logarithmic transformation for known ET
independent runs during the execution of the study.
steady-state levels for 6 hours after probe placement.
ization of the bioactive peptide around the probe, whicbeen directly measured in humans. Accordingly, the overall
The Journal of Thoracigoal of this study was 2-fold: first, to determine the rela-
tionship between systemic and myocardial levels of ET in
patients undergoing cardiac surgery; second, to examine
myocardial levels of ET within the myocardium of patients
during and immediately after CPB.
Methods
Patients
The protocol was approved by the Human Subjects Review Com-
mittee of the Medical University of South Carolina and the Vet-
terstitial (A, 0.003 to 1 fmol/mL) and plasma (B, 1 to 32
t of bound and total ligand ET (B/B0), and the y-axis
entrations. The standard curves were repeated in 10
vivo measurements of interstitial ET demonstrated
ion of radiolabeled ET demonstrated compartmental-
s immediately recovered at termination of the infusion.th in
otien
conc
C, In
Infuserans Affairs Medical Center. Twenty patients undergoing elective
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CSPcoronary artery bypass surgery requiring CPB provided informed
consent to participate in this study. Demographic and perioperative
data for these patients are provided in Table 1. Initial cardioplegia
was accomplished with antegrade administration of 200 to 250 mL
of normothermic cardioplegic solution containing 4 parts blood to
1 part D5W 0.2 NaCl containing 29 mL of tromethamine buffer, 34
mL of adenosine citrate phosphate dextrose, and 30 mEq/L of
KCL. This was followed immediately by retrograde administration
of 1000 mL of hypothermic (5°C) 4:1 blood:crystalloid cardiople-
gic solution. At 20-minute intervals cardioplegia was maintained
with retrograde administration of 200 to 500 mL of the cardiople-
gic solution with a lower KCl concentration (15 mEq/L). Before
removal of the crossclamp, a 500- to 750-mL dose of terminal
normothermic cardioplegic solution was given. At the termination
of CPB, heparin was neutralized with protamine in a 1:1 ratio.
Myocardial Microdialysis and Plasma Collection
Myocardial microdialysis studies have been performed previously
and the technique was adapted for this study.11-13 A probe con-
taining a 4 mm–long membrane was used (20 kDa; outer diameter
of probe shaft, 0.77 mm; outer diameter of probe membrane, 0.5
mm; CMA/Microdialysis, North Chelmsford, Mass). The probe
was placed into the LV apical midmyocardium and prepared for
dialysate collection. A radial artery was catheterized and used to
obtain systemic samples. Systemic and myocardial interstitial sam-
ples were collected at baseline and up to 30 minutes post-CPB.
ET Analytical Measurements
Plasma and dialysate samples were first eluted over a cation
exchange column (C-18 Sep-Pak; Waters Associates, Milford,
Mass) and then dried by vacuum centrifugation. The samples were
reconstituted in 0.02 mol/L borate buffer, and a high-sensitivity
radioimmunoassay was performed (RPA 545, Amersham, Arling-
ton Heights, Ill). After incubation of samples with 125I-labeled ET
TABLE 1. Patient characteristics and perioperative data
Sample size (n) 20
Age (y) 62 9
Sex
Male 15
Female 5
Ejection fraction (%) 53 11
Medication profile (% of sample size)
Beta blockade 55
Ca2 channel blockers 35
ACE inhibitors 15
Diuretics 15
HMG-CoA reductase inhibitors (statins) 20
No. grafts 3 1
Crossclamp duration (min) 68 15
Cardiopulmonary bypass duration (min) 87 17
Surgery duration (min) 258 44
Duration of stay in intensive care unit (d) 2.4 1.1
Postoperative hospital stay (d) 9 5
Values presented as mean  standard deviationand ET specific antibody, a charged secondary antibody was
586 The Journal of Thoracic and Cardiovascular Surgery ● Maradded. Bound and free labels were magnetically separated. Two
sets of standards were constructed to support the range of ET
within the 2 sample sets: 0.003 to 1.0 fmol/mL for the interstitial
samples and 2.0 to 32.0 fmol/mL for the plasma samples. Although
past studies have reported ET levels in picograms per milliliter,8,9
the present study as well as more recent reports have used a
high-sensitivity assay that allows for ET measurements to be
reported within the fentomolar range.6,11 A standard curve used for
the plasma and microdialysis samples, which demonstrates the
high sensitivity and operating range of this assay system, is shown
in Figure 1. The interassay variation was 7% and 2% for the
plasma and microdialysis ET measurements, respectively. The
plasma ET concentrations were corrected for potential hemodilu-
tion artifact by using changes in hematocrit.
Microdialysis Calibration
The first set of calibration experiments determined the relative
recovery of ET in the microdialysis system using a 125I-ET tracer
as described previously.11 The relative recovery of ET at a flow
rate of 2.5 L/min was calculated to be 15%  1%, and this value
was used as the correction factor for recovery of myocardial
interstitial samples. A second set of validation experiments were
performed in vivo in an anesthetized pig preparation described
previously.11,14 All animals were treated and cared for in accor-
dance with the National Institutes of Health “Guide for the Care
and Use of Laboratory Animals” (National Research Council,
Washington, DC, 1996). In brief, adult pigs (n  3, 25 kg,
Hambone Farms, Orangeburg, SC) were anesthetized with isoflu-
Figure 2. Systemic ET levels increased from baseline during CPB,
at separation from CPB, and 30 minutes after CPB. Systemic ET
levels were also higher 30 minutes after CPB as compared with
pre-CPB values. Myocardial interstitial ET levels increased from
baseline at all time points and also increased from pre-CPB
values. Myocardial interstitial ET levels were higher than sys-
temic ET at all time points. *P < .05 vs baseline; P < .05 vs
pre-CPB; ‡P < .05 vs systemic ET. CPB, Cardiopulmonary bypass;
CCR, crossclamp release.rane (3%), microdialysis probes placed, and ET microdialysis
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Pmeasurements performed for up to 6 hours. ET values at 1- and
6-hour time points were 24 7 and 25 8 fmoL/mL, respectively
(P  .82). Thus, this microdialysis technique yielded reproducible
interstitial ET values over time. To confirm that probe placement
did not impede diffusion as well as reached a steady state within
the interstitial compartment, a 125I-ET solution (20 fmol/mL, 2.5
uL/min, Amersham) was infused and dialysate radioactivity deter-
mined (Figure 1). At the end of the 125I-ET infusion period, the
dialysate was immediately changed (using a servo-control system,
CMA) to buffer and collection continued. 125I-ET reached steady-
state levels by approximately 30 minutes. These results indicated
a balance between the rate of 125I-ET infusion and the return of
radiolabeled ET in the dialysate. With termination of the 125I-ET
infusion, the dialysate concentration of radiolabeled ET fell in a
time-dependent manner. After these experiments, the tissue was
harvested and sections taken at 2-mm intervals from the probe tip.
All the radioactive ET-1 remained compartmentalized within a
4-mm radius around the probe, as no 125I-ET was detected in
samples taken from greater distances. Thus, the radiolabeled ET
remained within the interstitial space surrounding the microdialy-
sis probe and could be modeled as a closed compartment system.
Data Analysis
Plasma and interstitial ET levels at each time point were evaluated
TABLE 2. Hemodynamic parameters before, during and aft
Baseline (p
Heart rate (beats/min) 72 3 71
Cardiac output (L/min) 4.38 0.21 4.40
Pressures
Mean arterial (mm Hg) 78 3 76
Mean pulmonary artery (mm Hg) 14 1 16
Pulmonary capillary wedge (mm Hg) 10 1 10
Values presented as mean  SEM.
*P  .05 versus baseline.
†P  .05 versus pre-CPB (30-minute time point).
TABLE 3. Basal plasma and myocardial interstitial endothe
channel blockers
Plasma
Sex
Male (n  15) 3.41 0.29
Female (n  5) 2.54 0.37
Beta blockade (-blocker)
Receiving -blocker (n  11) 2.77 0.26
No -blocker (n  9) 3.70  0.40
Ca2 channel blockade (CCB)
Receiving CCB (n  7) 2.87 0.36
No CCB (n  13) 3.36 0.33
Values presented as mean  SEM.with a 2-way analysis of variance (ANOVA). If the ANOVA
The Journal of Thoracirevealed significant differences, individual group means were
compared by pairwise adjusted Bonferroni probabilities. All sta-
tistical procedures were performed with the BMDP statistical
software package (BMDP Statistical Software Inc, Los Angeles,
Calif). Patient characteristics and perioperative data are presented
as mean  SD. For categorical data such as graft number and
incidence of pharmacologic support, a chi-square analysis was
performed. All analytical parameters are presented as mean 
SEM.
Results
Global hemodynamic parameters during the course of the
sampling period are shown in Table 2. At 30 minutes after
CPB, cardiac output was higher and mean arterial pressure
lower relative to baseline. Baseline myocardial interstitial
ET levels were approximately 6-fold higher than systemic
levels (Figure 2). There was a trend for patients receiving a
beta-receptor antagonist to have lower plasma ET levels
(Table 3). Before CPB, myocardial interstitial ET levels
were higher than systemic plasma levels. Both the myocar-
dial interstitial and plasma levels increased during CPB, and
systemic ET levels increased from baseline during CPB and
ardiopulmonary bypass (CPB)
Time (min)
B)
60 90 120
(off CPB)
150 (probe
removed)CPB
— — 79  3 78  2
.23 — — 4.65 0.21 5.10 0.15*†
69  3* 72  2 75 4 76  3
— — 13  1 17  1*
— — 8 1 9  1
evels (fmol/mL): effects of gender, beta blockade, or Ca2
P value Interstitial P value
.1323 20.00 2.69 .9324
20.42 2.27
.0580 21.22 3.58 .5658
18.74 1.62
.3663 21.23 2.26 .7017
19.50 2.99er c
30
re-CP
 3
 0
 2
 1
 1lin lincreased further at separation from CPB and 30 minutes
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were higher than baseline values at all time points and
increased further on separation from CPB (Figure 2). Al-
though myocardial interstitial ET increased from baseline
for the majority of patients, 4 patients demonstrated a de-
crease or no change at 30 minutes after CPB (Figure 3).
Before surgery all 4 of these patients were receiving a
beta-adrenergic receptor antagonist and 3 of these 4 patients
were concomitantly receiving 95% of the patients at 6 hours
postoperatively with 40% of the patients remaining on this
vasodilator at 24 hours postoperatively. At 6 hours postop-
eratively, 60% of the patients were on intravenous epineph-
rine and all patients were removed from this vasoactive
agent by 24 hours postoperatively. The intraoperative inter-
stitial ET levels were not associated with the presence or
absence of postoperative nitroglycerin or epinephrine ad-
ministration. Duration of stay in intensive care unit was also
not associated with intraoperative interstitial ET levels.
However, an apparent relationship between postoperative
length of stay (LOS) was observed with baseline myocardial
interstitial ET levels. Specifically, in patients with a basal
myocardial interstitial ET level of less than 15 fmol/mL,
LOS was 6.0 0.5 days whereas in patients with interstitial
ET levels of greater than 15 fmol/mL, LOS was 10.1  1.3
days (P  .05).
Discussion
Postoperative LV pump dysfunction can occur after cardio-
plegia and CPB.4,6-10 The causes of this LV dysfunction are
likely to be multifactorial and include neurohormonal sys-
tem activation, changes in vascular resistance properties,
and abnormalities in myocardial contractility.6,10,15-17 In the
Figure 3. The individual response plots with respect to myocar-
dial interstitial ET at baseline and 30 minutes after CPB was
examined. Although the majority of patients demonstrated an
increase from baseline, approximately 4 patients decreased or
had no change from baseline.context of cardiac surgery, increased systemic plasma ET
588 The Journal of Thoracic and Cardiovascular Surgery ● Marlevels have been documented, which may affect systemic
and pulmonary vascular resistance, the caliber/patency of
the coronary conduits, and myocardial contractili-
ty.1,5,6,14,15,18-22 The present study used a precalibrated
myocardial microdialysis system to measure the dynamics
of ET within the interstitial compartment during and after
myocardial arrest and CPB. The unique and important find-
ings of the present study were 2-fold. First, ET levels were
over 6-fold higher within the myocardial interstitium com-
pared with simultaneous plasma measurements, indicating
significant compartmentalization of this bioactive peptide
within the human myocardium. Second, distinct and tem-
porally disparate changes in myocardial interstitial ET oc-
curred during and after CPB when compared with systemic
plasma levels.
This is the first study that has placed a microdialysis
probe in the human myocardium to measure changes in ET
during and after cardioplegia and CPB. Past studies have
employed similar techniques to interrogate the myocardial
interstitium for the elaboration of relevant proteins in ani-
mal models.11-13 Dell’Italia and colleagues, 12 using myo-
cardial microdialysis, demonstrated that interstitial angio-
tensin II levels were 100-fold greater than that of plasma,
indicating compartmentalization of this bioactive peptide.
Using a pig model of heart failure, this laboratory has
demonstrated previously that myocardial interstitial levels
are significantly different than plasma levels and likely
reflect alterations in synthesis and/or uptake by myocardial
cells.11 These past studies also demonstrated that neurohor-
monal measurements performed in myocardial tissue ho-
mogenates will not reflect the dynamic nature of these
signaling molecules. The present study builds on these past
findings by interrogating the human myocardium for inter-
stitial ET levels during and after cardioplegia and CPB.
Specifically, myocardial interstitial ET levels increased
early during CPB, whereas systemic ET levels remained
unchanged from baseline. At separation from CPB, another
surge in interstitial ET occurred, which was greater in
magnitude than systemic levels. The results of the present
study indicate that there is a clear compartmentalization of
ET within the human myocardial interstitial space.
The present study demonstrated through the use of mi-
crodialysis that significant and prolonged exposure of the
myocardial cells to ET occurs during and after cardioplegia
and reperfusion. Past studies have shown that persistent ET
receptor activation after cardioplegia can independently
contribute to myocyte contractile dysfunction, which in turn
could lead to an exacerbation of LV contractile dysfunction
in the early setting after cardiac surgery.14 Although the
present study was underpowered to properly address this
issue, a past study with larger sample sizes documented
increased inotropic requirements after CPB in those patients
with higher intraoperative plasma ET levels.7 In a past study
ch 2005
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Pby Matheis and colleagues,9 systemic and coronary sinus
levels of ET increased in a directional manner in patients
after CPB, suggesting that ET “spillover” from the myocar-
dial compartment had not occurred. Thus, whether and to
what degree these systemic plasma levels reflect changes
within the myocardial compartment remained unknown.
The present study demonstrated a robust increase in ET
levels within the myocardial interstitium after crossclamp
release, indicating that a significant accumulation of ET
occurred within the myocardial microenvironment, which
would not necessarily be detected through the measurement
of aortic and coronary sinus ET levels.
We demonstrated previously that the synthesis of ET
occurs within the myocardial compartment and can be con-
tained within cardiac myocytes.11 Moreover, this past study
demonstrated robust levels of the ET converting enzyme.
Local changes in pH and myocardial metabolism occur
immediately after CPB and can directly influence the syn-
thesis and release of several biologically active molecules
such as ET.23 Hypothermia can alter the binding kinetics of
the ET receptor,24 and therefore changes in myocardial
temperature may have caused unstable ET binding kinetics.
Based upon the findings of the present study, future studies
should utilize microdialysis to determine the relationship
between the release of endogenous ET, ET synthesis, and
ET receptor activation in the context of CPB.
In a small subset of patients, interstitial ET levels were
not increased with CPB. In these particular patients, 3 were
treated with a 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitor (statins) and all of these patients received
a beta-adrenergic receptor antagonist. Beyond reducing se-
rum cholesterol levels, statins have been implicated to mod-
ify the release of bioactive peptides, reduce the magnitude
of inflammatory response, and improve endothelial func-
tion.25,26 The synthesis and release of ET is under the
regulation of several neurohormonal/inflammatory path-
ways as well as through local mechanical signals.1-4 Thus,
the release of ET into the myocardial interstitial compart-
ment during and after CPB was likely due to a summation
of several upstream signaling events. Nevertheless, it can be
hypothesized from the observational data regarding preop-
erative statin and beta-blocker therapy, specific pharmaco-
logic pretreatment may modify the ET response during
cardiac surgery.
ET has been demonstrated to contribute to vasoconstriction
within the systemic and pulmonary circulatory systems.5-
10,14,22 Systemic ET levels have been documented to increase
during and after CPB.6-10 Specifically, Dorman and colleagues
demonstrated a robust increase in plasma ET after CPB.7 As
past studies have demonstrated a cause-effect relationship be-
tween ET receptor activation and blood pressure,5,14,18,22,23
then increased circulating levels of ET observed in the present
study likely influence both systemic and pulmonary vascular
The Journal of Thoraciresistance properties. Increased plasma ET levels in the post-
operative period have been associated with longer ventilatory
support and prolonged intensive care unit times and hospital
stay.6,7 The present study demonstrated that higher baseline
myocardial interstitial ET levels were associated with a longer
postoperative hospital stay. However, this study was under-
powered with respect to performing any predictive analysis on
postoperative outcomes variables. Finally, a direct cause-and-
effect relationship between elevated myocardial interstitial ET
levels and adverse outcomes (ie, coronary vasospasm, de-
pressed myocardial performance) could not be directly estab-
lished in this limited study. Nevertheless, this unique intraop-
erative study clearly demonstrated that dynamic ET signaling
changes occur within the myocardial interstitium of patients
undergoing cardiac surgery. Future studies that directly relate
the dynamic changes in myocardial interstitial ET levels to
myocardial performance and clinical outcomes, as well as
deploying pharmacological strategies that interrupt ET signal-
ing in the perioperative cardiac surgical setting, are warranted.
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